Abstract P4-10-08: Impact of an Online Educational Activity on Oncologists’ Knowledge and Confidence Regarding the Management of HR-Positive/HER2-Negative Metastatic Breast Cancer

Abstract Background: The management of HR+/HER2− metastatic breast cancer (mBC) is evolving with the introduction of novel therapies, particularly in the post-CDK 4/6 inhibitor setting. The objective of this study was to assess if an online continuing medical education (CME) activity could improve oncologists’ knowledge of the latest evidence regarding novel and emerging therapies for HR+/HER2− mBC. Methods: This educational activity consisted of a 30-minute video presentation with synchronized slides, including a whiteboard animation illustrating the mode of action of novel agents. Educational effect was assessed using a repeated-pair design with pre-/post-assessment. 3 multiple choice questions assessed knowledge, and 1 question rated on a Likert-type scale assessed confidence, with each individual serving as their own control. A chi-squared test assessed significance of improvement in the percentage of correct responses to knowledge questions from pre- to post-assessment. P values < .05 are statistically significant. The activity launched on 25th of August 2023, with data collected through 11th December 2023 being reported in the current study. Results: The analysis set consisted of responses from oncologists (n=59) who answered all assessment questions during the study period. Analysis of pre- vs post-intervention responses demonstrated a significant improvement in oncologists’ overall knowledge (P< .01). Overall correct responses increased from 57% pre- to 75% post-CME. Specific areas of improvement include: Knowledge of the latest clinical data of emerging therapies for HR+/HER2− mBC (pre 65%, post 80%; P < .01). Knowledge of the mode of action of novel agents for HR+/HER2− mBC (pre 41%, post 64%; P < .01). After education, 44% of oncologists had a measurable increase in confidence in their ability to identify patients suitable for participation in clinical trials investigating novel treatment, and that increase was, on average, 64%. Conclusions: This study demonstrates the success of an online, 30-minute CME activity on improving the knowledge and confidence of oncologists regarding the evolving treatment landscape of HR+/HER2− mBC, including in areas where many clinicians appeared to have relatively high knowledge levels at baseline. However, as new data continue to emerge, it will be important to provide ongoing education to clinicians so that they feel confident in interpreting the clinical evidence and translating it into practice. Citation Format: Zhizhi Fiske, Stephen Dunn, Deborah Grainger, Eloise Ballard, Jamie Habib, Peter Schmid. Impact of an Online Educational Activity on Oncologists’ Knowledge and Confidence Regarding the Management of HR-Positive/HER2-Negative Metastatic Breast Cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P4-10-08.